Zadaxin (Thymalfasin) Approved In Thailand, Laos And Malta For Hepatitis B And C
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Zadaxin (Thymalfasin) Approved In Thailand, Laos And Malta For Hepatitis B And C

SAN MATEO, CA -- March 17, 2000 -- SciClone Pharmaceuticals announced that Zadaxin, the company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. Zadaxin now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatitis C. SciClone has filed for Zadaxin marketing approval in 18 additional countries.

Hepatitis B and hepatitis C are highly infectious liver diseases that can lead to cirrhosis, liver cancer and death. Worldwide, there are approximately 350 million long-term carriers of the hepatitis B virus, including approximately 1.2 million in the U.S. Approximately 170 million people worldwide are infected with the hepatitis C virus, including 4 million in the U.S. and 5 million in Europe.

Many patients with cancer and chronic infectious diseases have an impaired immune system. Zadaxin significantly enhances the immune system's ability to recognize and destroy cancerous and infected cells. Zadaxin immunotherapy is in late-stage development for cancer and viral hepatitis worldwide.

SciClone Pharmaceuticals is a global biopharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. The Company has focused its current product development and commercialization activities on cancer, hepatitis B, hepatitis C, drug-resistant tuberculosis and cystic fibrosis.

Related Links: Zadaxin and SciClone Pharmaceuticals.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities